By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Biotechnology. According to news reporting originating from Baltimore, Maryland, by NewsRx correspondents, research stated, "We have previously created a potent DNA vaccine encoding calreticulin linked to the human papillomavirus (HPV) oncogenic protein E7 (CRT/E7). While treatment with the CRT/E7 DNA vaccine generates significant tumor-specific immune responses in vaccinated mice, the potency with the DNA vaccine could potentially be improved by co-administration of a histone deacetylase inhibitor (HDACi) as HDACi has been shown to increase the expression of MHC class I and II molecules."
Our news editors obtained a quote from the research from Johns Hopkins University, "Thus, we aimed to determine whether co-administration of a novel HDACi, AR-42, with therapeutic HPV DNA vaccines could improve the activation of HPV antigen-specific CD8(+) T cells, resulting in potent therapeutic antitumor effects. To do so, HPV-16 E7-expressing murine TC-1 tumor-bearing mice were treated orally with AR-42 and/or CRT/E7 DNA vaccine via gene gun. Mice were monitored for E7-specific CD8(+) T cell immune responses and antitumor effects. TC-1 tumor-bearing mice treated with AR-42 and CRT/E7 DNA vaccine experienced longer survival, decreased tumor growth, and enhanced E7-specific immune response compared to mice treated with AR-42 or CRT/E7 DNA vaccine alone. Additionally, treatment of TC-1 cells with AR-42 increased the surface expression of MHC class I molecules and increased the susceptibility of tumor cells to the cytotoxicity of E7-specific T cells. This study indicates the ability of AR-42 to significantly enhance the potency of the CRT/E7 DNA vaccine by improving tumor-specific immune responses and antitumor effects. Both AR-42 and CRT/E7 DNA vaccines have been used in independent clinical trials; the current study serves as foundation for future clinical trials combining both treatments in cervical cancer therapy."
According to the news editors, the research concluded: "Key message AR-42, a novel HDAC inhibitor, enhances potency of therapeutic HPV DNA vaccines AR-42 treatment leads to strong E7-specific CD8+ T cell immune responses AR-42 improves tumor-specific immunity and antitumor effects elicited by HPV DNA vaccine AR-42 is more potent than clinically available HDACi in combination with HPV DNA vaccine."
For more information on this research see: Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. Journal of Molecular Medicine-Jmm, 2013;91(10):1221-1231. Journal of Molecular Medicine-Jmm can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA (see also technology.html">Biotechnology).
The news editors report that additional information may be obtained by contacting S.Y. Lee, Johns Hopkins Sch Med, Dept. of Pathol, Baltimore, MD 21231, United States. Additional authors for this research include Z.M. Huang, T.H. Kang, R.S. Soong, J. Knoff, E. Axenfeld, C.G. Wang, R.D. Alvarez, C.S. Chen, C.F. Hung and T.C. Wu.
Keywords for this news article include: Biotechnology, Maryland, Baltimore, Treatment, Immunology, CD Antigens, Vaccination, CD8 Antigens, DNA Research, DNA Vaccines, Immunization, Therapeutics, United States, Nucleoproteins, Amidohydrolases, Differentiation, Biological Factors, Synthetic Vaccines, Biological Products, Histone Deacetylases, Human Papillomavirus
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC